Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Expression Pathology, a developer of technology for tissue protein analysis, has received additional financing of $6.5 million. The financing was led exclusively by Abraxis BioScience, a fully integrated, biotechnology company.
Subscribe to our email newsletter
The financing will be used to apply Expression Pathology’s patented Liquid Tissue proteomics technology in developing personalized medicine clinical assays that relate measurement of protein biomarkers of drug response and disease prognosis to specific patient treatment decisions.
Casey Eitner, president and CEO of Expression Pathology, said: “We believe the ability of our technology to interrogate archived tissue collections to discover and validate protein biomarkers that relate to disease progression, drug response and toxicity, and to measure those biomarkers accurately in standard tissue from clinical trials and medical care, will translate into a tremendously valuable asset. We are pleased that Abraxis shares this vision.”